Display Settings:

Format

Send to:

Choose Destination

    Neurology. 2005 Feb 22;64(4):743-5.

    Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease.

    Ramirez-Montealegre D, Chattopadhyay S, Curran TM, Wasserfall C, Pritchard L, Schatz D, Petitto J, Hopkins D, She JX, Rothberg PG, Atkinson M, Pearce DA.

    Aab Institute of Biomedical Sciences, Center for Aging and Developmental Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.

    The pathogenic mechanisms underlying Batten disease are unclear. Patients uniformly possess autoantibodies against glutamic acid decarboxylase (GAD) that are predominantly reactive with a region of GAD (amino acids 1 to 20) distinct from subjects with autoimmune type 1 diabetes or stiff-person syndrome. Batten patients did not possess autoantibodies against other type 1 diabetes-associated autoantigens and human leukocyte antigen genotypes revealed no specific associations with this disease.

    PMID: 15728308 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read Click here to read